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Monocyte chemoattractant protein-1 (MCP-1, CCL2) is produced by many diﬀerent types of cells. In the current investigation, the
eﬀect of tumor-derived CCL2 on macrophages was evaluated to determine the extent to which this chemokine inﬂuenced the innate
immune response to cancer. To do this, we used the 4T1 murine mammary carcinoma cell line that constitutively expresses CCL2
and generated 4T1 expressing an antisense CCL2 transcript. The antisense-CCL2-expressing 4T1 produced no detectable CCL2.
MacrophagesfromfemaleBALB/cmicewereexposedtosupernatantsfromthesetumorcells.Theresultsshowedthattumor-derived
CCL2 was capable of modulating cytokine gene expression but not protein production in resting, activated, and tumor-associated
macrophages. In addition, tumor-derived CCL2 did not aﬀect phagocytic activity, nitric oxide production, or cytolytic activity of
the macrophages. Overall, these data suggest that tumor-derived CCL2 does not directly inﬂuence macrophage-mediated antitumor
activity.
INTRODUCTION
CCL2 is produced by many cell types such as T cells,
monocytes, and even many tumor cells. It is a potent
chemoattractant for monocytes and induces the expres-
sion of integrins required for chemotaxis [1, 2]. Simi-
lar to many other members of the CC chemokine fam-
ily, CCL2 is also a chemoattractant for activated CD4 and
CD8+ T cells and natural killer (NK) cells [3, 4]. Further,
it is capable of triggering granule release from NK cells
and CD8+ T cells and inducing histamine-releasing fac-
torfrombasophils[5,6].Unfortunately,despitebeingone
of the most frequently investigated chemokines in tumor
immunology, the role of tumor-derived CCL2 in tumor
immunity remains unclear [7].
Although several studies have reported that intro-
ducing the CCL2 gene into tumor cells reduces tumori-
genicity and increases monocyte inﬁltration and cytolysis
[8, 9, 10, 11, 12], other studies have reported that tumor-
derived CCL2 correlates with enhanced metastasis, angio-
genesis, and tumor progression [13, 14, 15]. The conﬂict-
ing results indicate a need for further clariﬁcation of the
inherent paradox that lies within this chemokine’s activi-
ties. The need to clarify the role of tumor-derived CCL2
in patients with breast cancer is further justiﬁed due to
the fact that expression may serve as an indicator of early
relapse [14].
Inanattempttofacilitatetheunderstandingoftumor-
derived CCL2, we have been using murine mammary car-
cinoma models. Previously we reported that the murine
mammary carcinoma 4T1 and spontaneous tumors from
rat neu transgenic mice constitutively express CCL2 [16,
17]. Subsequently, we explored the role of tumor-derived
CCL2 in the T cell response to the 4T1 mammary carci-
noma and found that it was capable of impairing the T
cell response to this tumor [18]. Here, we are interested
in determining whether tumor-derived CCL2 inﬂuenced
macrophage eﬀector function.
For this purpose, we compared the ability of mac-
rophages to respond to 4T1 that expressed diﬀerent
levels of CCL2. Thus, resting and activated peritoneal
macrophagesfromBALB/cmicewereexposed to4T1that
expressed normal levels of CCL2 and 4T1 that expressed
an antisense CCL2 eukaryotic expression vector which
produced no detectable CCL2. The macrophages were
then assayed for cytokine gene expression, protein pro-
duction, as well as phagocytic activity, nitric oxide (NO)
production, and cytolytic ability. Collectively, the study
revealed that tumor-derived CCL2 could modulate cy-
tokine gene expression but not protein production. Also,
tumor-derived CCL2 did not signiﬁcantly modulate the
phagocyticactivity,NOproduction, orthecytolyticactiv-
ity of the macrophages. Consequently, these data indicate
that tumor-derived CCL2 does not directly inﬂuence the
ability of macrophages to exert antitumor immunity.
MATERIAL AND METHODS
Miceandtumorcells
Six to eight week old female BALB/c mice were pur-
chased from the Jackson Laboratory (Bar Harbor, Me)
and provided food and water ad libitum. The vector38 M. S. Brault and R. A. Kurt 2005:1 (2005)
transfected control 4T1 tumor cells (A4) and antisense
CCL2 transfected 4T1 tumor cells (G7) were created and
maintained in complete Roswell Park Memorial Institute
(cRPMI) media as previously described [18].
Macrophageisolationandpuriﬁcation
Activated and resting macrophage populations
were used throughout the investigation. Activated
macrophages were collected from mice treated with 1mL
of 3% thioglycollate (Sigma, St. Louis, Mo) injected
into the peritoneal cavity (IP). Four days after injection
the mice were sacriﬁced and 10mL of cRPMI were
injected into the peritoneal cavity and extracted to collect
the peritoneal exudate. Red blood cells were lysed by
hypotonic shock. Resting macrophages were collected in
a similar manner from untreated mice.
Magnetic cell separation was used to enrich macro-
phages from the peritoneal exudates. CD11b microbeads
(Miltenyi Biotec, Auburn, Calif) were used to do this ac-
cording to the manufacturer’s instructions. The resulting
cellpopulationwas92%–97%pureCD11b+ macrophages
basedupondiﬀerentialcellcounts.Diﬀerentialcellcounts
were performed by centrifuging 5 × 104 cells onto a slide
using a Cytospin (Thermo-Shandon, Pittsburgh, Pa). The
cells were stained with the Hema 3 stain kit (Fisher Scien-
tiﬁc, Pittsburgh, Pa) and the percent macrophages, neu-
trophils, and lymphocytes were determined by morphol-
ogy from three separate ﬁelds of view/slide.
Reversetranscriptase-polymerasechainreaction
To evaluate cytokine gene expression, messenger RNA
(mRNA) was isolated using the mRNA isolation kit (Qi-
agen, Chatsworth, Calif). Complementary DNA (cDNA)
was generated using 1µL random hexamer primers
(Promega, Madison, Wis), 200 units of M-MLV RT
(Promega), and 2mM dNTP at 42 ◦Cf o r1h o u r .A n
aliquot (3µL) of the cDNA along with 15µLo fp r i m e r s
was then subjected to semiquantitative PCR with taq
polymerase (94 ◦C for 15 seconds, 59 ◦C for 30 seconds,
72 ◦C for 45 seconds) for 30 cycles on a thermocycler
(MJ Research, Waltham, Mass). The cytokine-speciﬁc
primers were synthesized by Integrated DNA Technolo-
gies (Coralville, Iowa):
(i) GAPDH (212 bp product size)
forward 5 -CAGGTTGTCTCCTGCGACTT-3 
reverse 5 -CTTGCTCAGTGTCCTTGCTG-3 ,
(ii) IL-12 p40 subunit (482 bp product size)
forward 5 -GGAAGCACGGCAGCAGAATAA-3 
reverse 5 -AGCCAACCAAGCAGAAGACAG-3 ,
(iii) TNF-α (283 bp product size)
forward 5 -CCAGGAGGGAGAACAGAAACT-3 
reverse 5 -CAGTAGACAGAAGAGCGTGGTG-3 ,
(iv) IL-18 (219 bp product size)
forward 5 -CTGGCTGTGACCCTCTCTGT-3 
reverse 5 -AGCATCATCTTCCTTTTGGC-3 .
RT-PCR products were analyzed on a 2% agarose gel
with ethidium bromide (Sigma), and analyzed using a gel
documentation system (Alpha Innotech Corp, San Lean-
dro, Calif).
CytokineandNOproduction
To evaluate cytokine and NO production, macro-
phageswereexposedtoA4(CCL2+)andG7(CCL2−)tu-
mor supernatants. The A4 and G7 supernatants were ob-
tainedbyplating1×106 cells/wellina24-wellﬂat-bottom
cell culture plate (BD Falcon, Franklin Lakes, NJ) in 1mL
of cRPMI. The supernatants were collected after a 24-
hour incubation at 37 ◦Ca n d5 .0% CO2,c e n tri f u g e df o r5
minutes at 350xg, transferred to sterile microfuge tubes,
and stored at −20 ◦C. Macrophages were then plated at
1×106 cells/well in 1mL of either the A4 or G7 tumor su-
pernatant and incubated at 37 ◦C for 24 hours. Following
the incubation, supernatants were harvested and assayed
for cytokines by speciﬁc ELISA or NO content according
tomanufacturer’sinstructions(R&DSystems,Minneapo-
lis, Minn). Messenger RNA was isolated from the same
macrophages and used to examine cytokine gene expres-
sion.
For analysis of tumor-associated macrophages
(TAM), four-week subcutaneous A4 and G7 tumors
were harvested and digested in a collagenase cocktail
(1mg/mL collagenase type IV, 20µg/mL DNase, 10U/mL
hyaluronidase). Macrophages were enriched from the
tumor digest as described above for the peritoneal
macrophages and cultured at 1 × 106 cells/well. Twenty-
four-hour supernatants from the TAM were assayed for
cytokine production by ELISA.
Phagocyticactivity
To examine phagocytic activity, Ec o l iBioParticles
(MolecularProbesInc,Eugene,Ore)werereconstitutedin
2mM sodium azide and phosphate-buﬀered saline (PBS)
at 20mg/mL. Ec o l iand opsonizing reagent (Molecular
Probes) were added in equal volumes to a microfuge tube,
vortexed, and incubated at 37 ◦Cf o r1h o u rt oa l l o wa d -
equate conjugation of antibodies to Ec o l i . After being
washed with PBS, the opsonized Ec o l iwere counted and
resuspended in PBS at 1 × 108 cells/mL. Next, activated
macrophages cultured in 1mL of A4 or G7 supernatants
for 24 hours were added onto 12mm round poly-L-lysine
coated coverslips (Becton Dickinson, Bedford, Mass). La-
beled BioParticles, 1 × 106 Ec o l i , were added directly to
the wells at a 10 : 1 ratio (Ec o l i:m a c r o p h a g e ) .F o l l o w i n g
a 30-minute incubation at 37 ◦C, nonphagocytosed Ec o l i
were washed away with PBS and the coverslips were pre-
pared for viewing by confocal microscopy using slowfade
antifade reagent (Molecular Probes, Eugene, Ore). Diﬀer-
ential phagocytic activity was measured from three sepa-
rate ﬁelds of view/slide.
Cytolyticactivity
In order to measure the cytolytic ability of acti-
vated macrophages exposed to tumor-derived CCL2,
macrophages were resuspended in 1mL of either A4 or2005:1 (2005) Tumor-Derived CCL2 Does Not Enhance Macrophage Function 39
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Figure 1. Tumor-derived CCL2 production. Supernatants were
taken from A4 and G7 tumor cells at diﬀerent time points and
evaluated for CCL2 production by ELISA. The data are repre-
sentative of three separate experiments with standard deviation
shown.
G7 supernatants at 1 × 105 cells/mL. These cell suspen-
sions were placed in separate wells, in a 24-well culture
plate, with 1 × 103 4T1 tumor cells. Following a 72-hour
incubation at 37 ◦C, 5% CO2, the tumor cells were re-
moved by trypsinization. The macrophages which are re-
sistant to trypsin remained in the wells. The surviving tu-
morcellswerequantiﬁedusingtrypanblueexclusion,and
data were reported as percent killing compared to control
wells without macrophages.
Statisticalanalysis
All data are presented as a mean plus or minus the
standard deviation of the mean. Statistical comparisons
were made using a paired Student’s t test with a one-tailed
distribution.
RESULTS
Macrophagesandtumorcells
Forthisstudy,activatedandrestingmacrophageswere
collected from mice and exposed to supernatants from
4 T 1t h a tp r o d u c e dn o r m a ll e v e l so fC C L 2( A 4 )o r4 T 1
that lacked CCL2 expression (G7). CCL2 expression by
these cells is shown in Figure 1. The A4 cells produced
1000pg/mL of the chemokine over a 24-hour period,
while CCL2 levels were below detection (< 15pg/mL) for
G7 cells. Previously we reported that 4T1 produced ap-
proximately 850pg/mL of CCL2 [16]. Macrophages col-
lected na¨ ıve mice (resting macrophages) and mice that re-
ceived thioglycollate (activated macrophages) were easily
distinguishable based upon cell size. Although the tumor-
derived CCL2 had no distinguishable eﬀect on morphol-
ogy, the activated macrophages were consistently larger
than the resting macrophages (data not shown).
CCL2associatedalterationsincytokineexpression
To evaluate whether tumor-derived CCL2 inﬂuenced
cytokine gene expression in macrophages, semiquantita-
tive RT-PCR was used. For these experiments, mRNA
was isolated from macrophages exposed to supernatants
from A4 and G7 tumor cells to analyze IL-12, IL-18, and
TNF-α gene expression (Figure 2). Densitometric anal-
ysis revealed an increase in IL-18, and TNF-α expres-
sion from both activated and resting macrophages ex-
posed to A4 supernatants compared to those exposed to
G7 supernatants, while IL-12 expression was not detected
(Figure 2).
In order to determine whether the altered gene ex-
pressioncorrelatedwithproteinproduction,supernatants
from macrophages exposed to A4 and G7 supernatants
were harvested and assayed for cytokine levels by ELISA.
The data revealed no diﬀerence in TNF-α levels while
IL-18 and IL-12 were both below detection levels of
the ELISA, 25pg/mL for IL-18 and 4pg/mL for IL-12
(Figure 3a). Accordingly, gene expression did not corre-
late with protein expression for TNF-α and IL-18.
To determine whether higher concentrations of
CCL2 could inﬂuence cytokine production from the
macrophages, recombinant CCL2 (rCCL2) was used. Sur-
prisingly, IL-12 production showed a dose-dependent re-
lationship to rCCL2, whereas TNF-α did not (Figure 3b).
IL-18 levels were still below detection. For both TNF-
α and IL-12, the resting and activated macrophages
responded similarly to rCCL2. Consequently, tumor-
derived CCL2 could enhance TNF-α production, but IL-
12 was only induced with rCCL2.
In order to address whether a longer exposure to
tumor-derivedCCL2couldinﬂuencecytokineexpression,
we assayed cytokine production from TAM. For this pur-
pose, TAM from four-week A4 and G7 tumors grow-
ing in mice were evaluated for IL-12, IL-18, and TNF-α
production. After isolation and enrichment (70%–75%
pure CD11b+ macrophages), all three cytokines (IL-12
20pg/mL, IL-18 40pg/mL, TNF-α 800pg/mL) were de-
tected from the TAM. However, similar levels were found
in the A4 and G7 tumors indicating that tumor-derived
CCL2 did not inﬂuence their expression (Figure 3c).
CCL2associatedalterationsineffectorfunction
NO is a major secretory product of mammalian
cells that initiates host defense [19]. The amount of
NO secreted by macrophages is thus a reliable mea-
sure of macrophage eﬀector function. Supernatants from
macrophages incubated with A4 and G7 typically con-
tained 270µMo fN O( Figure 4a). The amount of
NO produced did not change signiﬁcantly whether the
m a c r o p h a g e sw e r ea c t i v a t e do rn a ¨ ıve, nor whether they
wereexposedtoA4orG7tumorsupernatants(Figure 4a).
As a result, tumor-derived CCL2 did not modulate NO
production by the macrophages.
To determine whether tumor-derived CCL2 inﬂu-
enced macrophage cytolytic activity, a cytotoxicity assay
was used. To measure the killing activity of 4T1 carci-
noma cells, activated macrophages were incubated with
the tumor cells and either A4 or G7 supernatants for 7240 M. S. Brault and R. A. Kurt 2005:1 (2005)
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Figure 2. Cytokine analysis by RT-PCR. Resting (a) and ac-
tivated (b) macrophages were examined for IL-12, IL-18, and
TNF-α expression. GAPDH was used as a positive control. The
data represent one of three separate experiments. For the den-
sitometric analysis, the optical densities were calculated by com-
parison to the positive control (GAPDH).
hours. There was no signiﬁcant diﬀerence in tumor cy-
tolysis by the macrophages (Figure 4b). Percent killing
activity of 4T1 tumor cells in the presence or absence of
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Figure 3. Cytokine production by ELISA. (a) Resting and acti-
vatedmacrophageswereexaminedforcytokineproductionafter
exposuretoA4andG7supernatants.Thedataarerepresentative
of three separate experiments. The error bars represent the stan-
darddeviationofthemeanofduplicatewellsanalyzedbyELISA.
(b) Following exposure of macrophages to rCCL2 (µg/mL), su-
pernatants were assayed for the same cytokines. (c) TAM har-
vested from four-week A4 and G7 tumors were analyzed for cy-
tokine production. The data shown are representative of three
separate experiments, with error bars denoting the standard de-
viation from the mean.2005:1 (2005) Tumor-Derived CCL2 Does Not Enhance Macrophage Function 41
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Figure 4. Macrophage eﬀector function. (a) Macrophages ex-
posed to A4 () and G7 () supernatants were evaluated for
total NO production by measuring the concentration of ni-
trite. The amount of nitrite was measured in three separate
experiments from duplicate wells by ELISA. Error bars rep-
resent the standard deviation of the mean. (b) Macrophages
were exposed to A4 and G7 supernatants for 72 hours to test
their ability to modulate cytolytic activity. The ﬁgure represents
macrophage-mediated cytolysis of the tumor cells. The data are
representative of three separate cell counts/experiment, with er-
ror bars showing standard deviation from the mean. (c) The
ability of macrophages exposed to A4 () and G7 () super-
natants to phagocytose Ec o l iwas determined through confocal
microscopy. Usingboth lightand ﬂorescence settings simultane-
ously, it was possible to distinguish phagocytosed bacteria. The
data are representative of two separate experiments where cell
counts were determined from three separate ﬁelds of view/slide.
Error bars represent standard deviation from the mean.
tumor-derivedCCL2was25%–30%.Thesedataindicated
that tumor-derived CCL2 did not modulate the cytolytic
ability of the macrophages.
Finally, we investigated whether tumor-derived CCL2
could inﬂuence the phagocytic activity of macrophages.
For this purpose, we assayed the ability of activated
macrophages to phagocytose ﬂuorescently labeled Ec o l i
BioParticles (Figure 4c). Diﬀerential phagocytosis was
measured by counting individual bacteria phagocytosed
in three separate ﬁelds of view/slide. The data indicated
no diﬀerence in the phagocytic ability of macrophages
e x p o s e dt os u p e r n a t a n t sf r o mA 4c o m p a r e dt oG 7t u -
mors. The number of Ec o l iengulfed by the macrophages
after exposure to A4 and G7 supernatants is shown in
Figure 4c. A comparison of phagocytosis based upon
whether the macrophages engulfed any Ec o l i ,r e g a r d -
less of number, also showed no diﬀerence (data not
shown). Therefore, tumor-derived CCL2 did not inﬂu-
ence macrophage phagocytic activity.
DISCUSSION
As one of the ﬁrst chemokines used to genetically
modifytumorcells,CCL2hasbeeninvestigatedinanum-
ber of diﬀerent models. For instance, it was found that
chinese hamster ovary (CHO) cells transfected with ei-
ther human or murine CCL2 gene lose their ability to
form tumors in nude mice [20]. Similar results were ob-
tained when CCL2 expressing cells were injected with
nonexpressing CHO or HeLa cells [20]. When the B78/HI
melanoma cell line was transfected with the CCL2 gene,
a signiﬁcant delay in tumor growth was observed in syn-
geneic and nude mice [21].
Whether CCL2 expression could aﬀect metastatic po-
tential and macrophage susceptibility has also been in-
vestigated. Huang et al [9] reported that CCL2 decreased
the tumorigenicity and metastatic potential of the CT26
cell line. The CCL2 expressing tumors were also highly
susceptible to lysis by lipopolysaccharide (LPS) stimu-
lated macrophages [9] .T h es a m eg r o u ps h o w e ds i m i l a r
ﬁndings using the murine renal adenocarcinoma cell line
RENCA [10]. Another group used the C20 colon carci-
noma line and reported that the combination of CCL2
gene transfection and LPS delivery enhanced antitumor
immunity [11]. However, since CCL2 expression has been
correlated with progression in patients with breast can-
cer, a role for CCL2 in increasing tumorigenicity has also
been hypothesized [14]. One of the proposed mecha-
nisms by which CCL2 could enhance tumorigenesis is
by enhancing the synthesis of macrophage-derived TNF-
α since TNF-α has been shown to stimulate angiogene-
sis [22, 23]. In fact, there is evidence for such an asso-
ciation in a murine model. A comparison of two related
murine mammary adenocarcinoma cell lines revealed a
direct correlation between tumorigenicity and CCL2 ex-
pression [15]. The Ly-6hi DA3 cell line expressed high42 M. S. Brault and R. A. Kurt 2005:1 (2005)
levels of CCL2 and was more malignant than the Ly-6lo
DA3 cell line that expressed lower levels of CCL2.
Here we investigated whether tumor-derived CCL2
coulddirectlyinﬂuencemacrophageeﬀectorfunction.We
report that tumor-derived CCL2 is capable of modulat-
ingcytokinegeneexpression,butnotcytokineproduction
inmurineperitonealmacrophagesobtainedfromBALB/c
mice. The fact that cytokine production was not mod-
ulated by tumor-derived CCL2 was surprising and con-
tradictory to several other reports. Our data may diﬀer
from other reports due to the fact that we did not use
LPS to stimulate the macrophages. For instance, Seki et
al [24] reported 600pg/mL of IL-18 produced by Kupﬀer
cells stimulated with LPS, and TNF-α levels of approxi-
mately 3000pg/mL. The IL-12 results were also interest-
ing because 1000µg/mL of rCCL2 induced IL-12 expres-
sion, whereas tumor-derived CCL2 (also at 1000µg/mL)
did not. It is interesting to speculate that there is another
factor produced by these tumors that suppresses the IL-12
production and thus counters the eﬀect of tumor-derived
CCL2.
The cytotoxicity data also contrasted with previous
reports that CCL2 modulates macrophage mediated cy-
totoxicity [9]. Again, our results may diﬀer from others
because we did not use LPS to activate the macrophages.
Also, another study reported that modulation of tumor-
derived CCL2 did not inﬂuence monocyte mediated cyto-
toxicity in a signiﬁcant manner. Asano et al [25] inserted
the CCL2 gene or antisense transcript into two human
brain tumor cell lines; HBT28, which constitutively ex-
pressed high levels of CCL2, and HBT20, which expressed
lower levels of CCL2. Decreasing and increasing CCL2 ex-
pression in the tumor cells had a similar eﬀect on mono-
cyte mediated cytotoxicity.
Ultimately, this investigation has shown that tumor-
derived CCL2 may induce cytokine expression at the
mRNA level, but does not aﬀect protein production.
Moreover, tumor-derived CCL2 did not directly inﬂuence
the eﬀector function of the macrophages. The chemokine
was not able to modulate NO production, phagocytosis,
or tumor cytolysis. Consequently, the exclusive function
of tumor-derived CCL2 may be in aiding angiogenesis as
others have suggested [13, 22].
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